Abstract
Chemokines constitute a family of small heparin-binding proteins which orchestrate the infiltration of leukocytes during inflammation, but also directly influence other physiological and pathophysiological processes. In humans, more than 40 chemokines are known binding to around 18 G-protein-coupled receptors. A non-redundant role of certain chemokines and their receptors has been identified within the last years in inflammation and host defense. Among chemokine receptors, the CC chemokine receptors CCR1 and CCR2 have been shown to play a crucial role in these processes. Importantly, these receptors have already been targeted by specific antagonists in early human trials for autoimmune and infectious diseases. Although most of these antagonists failed to show any significant efficacy in the clinic, the knowledge of their biological effects could henceforth offer new avenues with optimal strategies for producing successful therapeutics.
Keywords: CCR1, CCR2, chemokine receptors, clinical trials, disease, small molecule antagonists.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:CCR1 and CCR2 Antagonists
Volume: 14 Issue: 13
Author(s): Henning W. Zimmermann, Viktor Sterzer and Hacer Sahin
Affiliation:
Keywords: CCR1, CCR2, chemokine receptors, clinical trials, disease, small molecule antagonists.
Abstract: Chemokines constitute a family of small heparin-binding proteins which orchestrate the infiltration of leukocytes during inflammation, but also directly influence other physiological and pathophysiological processes. In humans, more than 40 chemokines are known binding to around 18 G-protein-coupled receptors. A non-redundant role of certain chemokines and their receptors has been identified within the last years in inflammation and host defense. Among chemokine receptors, the CC chemokine receptors CCR1 and CCR2 have been shown to play a crucial role in these processes. Importantly, these receptors have already been targeted by specific antagonists in early human trials for autoimmune and infectious diseases. Although most of these antagonists failed to show any significant efficacy in the clinic, the knowledge of their biological effects could henceforth offer new avenues with optimal strategies for producing successful therapeutics.
Export Options
About this article
Cite this article as:
Zimmermann W. Henning, Sterzer Viktor and Sahin Hacer, CCR1 and CCR2 Antagonists, Current Topics in Medicinal Chemistry 2014; 14 (13) . https://dx.doi.org/10.2174/1568026614666140827144115
DOI https://dx.doi.org/10.2174/1568026614666140827144115 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases
Current Signal Transduction Therapy Editorial (Thematic Issue: Vascular Damage In Systemic Sclerosis)
Current Rheumatology Reviews Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Coagulation Factor Xa Inhibition: Biological Background and Rationale
Current Topics in Medicinal Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Letters in Drug Design & Discovery Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Cardioprotective Effects of Indian Gooseberry (Emblica officinalis Gaertn) and its Phytochemicals: A Review
Current Nutrition & Food Science Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Recent Advances in Methods of Puerarin Biotransformation
Mini-Reviews in Medicinal Chemistry Editorial [Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options]
Current Respiratory Medicine Reviews Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Astragalin Attenuates UVB Radiation-induced Actinic Keratosis Formation
Anti-Cancer Agents in Medicinal Chemistry